4basebio PLC
88Q.F
Get informed when a big investor buys or sells
+ FollowMarket Cap$98.33M
Close$
Share Statistics
| Market cap | $98.33 Million |
|---|---|
| Enterprise Value | $97.25 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.09 |
| Beta | 0.92 |
| Outstanding Shares | 15,538,518 |
Return
| Return on Equity | -289.02% |
|---|---|
| Return on Assets | -98.90% |
| Return on Invested Capital | -105.49% |
Valuation & Multiples
| P/E Ratio | -4.85 |
|---|---|
| PEG | -12.81 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 37.09 |
| Enterprise Value to EBIT | -3.45 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 1.65 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 25, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About 4basebio PLC
140 employees
CEO: Amy Jo Walker 4basebio PLC, an enterprise established in 2020 and situated in Cambridge, United Kingdom, is dedicated to the entire process, from conception to delivery, of synthetic DNA and RNA products. The company also provides advanced non-viral v...